How do you manage anemia associated with belzutifan therapy?
Answer from: Medical Oncologist at Academic Institution
Anemia is a common toxicity with belzutifan. In a recent pooled safety analysis (Choueiri et al., The Oncologist KCRS Meeting 2024), anemia was seen in 84% of patients (any grade; 29% grade 3) with a median time to onset of 29 days. It is an on-target effect resulting from HIF regulation of erythrop...
Comments
Medical Oncologist at Medical University of South Carolina I advise caution. Most tumors and chemoRx agents a...
at Johns Hopkins University The use of recombinant erythropoietin (rEPO) to co...
Medical Oncologist at Vanderbilt-Ingram Cancer Center Thanks for these comments. You are correct in that...
I advise caution. Most tumors and chemoRx agents a...
The use of recombinant erythropoietin (rEPO) to co...
Thanks for these comments. You are correct in that...